The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.

British journal of cancer ·Vol. 110 ·No. 2 ·2014-01-21 ·Pages 363-8

Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A

Abstract

Cell-free DNA (cfDNA) circulating in the blood holds a possible prognostic value in malignant diseases. Under malignant conditions, the level of cfDNA increases but the biological mechanism remains to be fully understood. We aimed to examine the correlation between cfDNA and total tumour burden defined by positron emission tomography (PET) parameters. Patients with advanced non-small cell lung cancer (NSCLC) were enrolled into a prospective biomarker trial. Before treatment, plasma was extracted and the level of cfDNA was determined by qPCR. An (18)F-fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) scan was performed and evaluated in terms of metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Tumour contours were delineated semi-automatically by a threshold standardised uptake value (SUV) of 2.5. The primary end point was correlation among cfDNA, MTV and TLG. The secondary end point was overall survival (OS) according to cfDNA, MTV and TLG. Fifty-three patients were included. There were no correlations between cfDNA and MTV (r=0.1) or TLG (r=0.1). cfDNA >75th percentile was correlated with shorter OS (P=0.02), confirmed in a multivariate analysis. MTV>the median was associated with a significantly shorter OS (P=0.02). There was no significant difference in OS according to TLG (P=0.08). Cell-free DNA may not be a simple measure of tumour burden, but seems to reflect more complex mechanisms of tumour biology, making it attractive as an independent prognostic marker.

MeSH Terms

Aged Aged, 80 and over Biomarkers, Tumor/blood Carcinoma, Non-Small-Cell Lung/blood,diagnosis,diagnostic imaging DNA, Neoplasm/blood Female Humans Lung Neoplasms/blood,diagnosis,diagnostic imaging Male Middle Aged Multimodal Imaging/methods Positron-Emission Tomography/methods Prognosis Prospective Studies Tomography, X-Ray Computed/methods Tumor Burden

Chemicals

Biomarkers, Tumor DNA, Neoplasm

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Nygaard A D

Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

Holdgaard P C

Department of Nuclear Medicine, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

Spindler K-L G

Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

Pallisgaard N

Department of Molecular Biochemistry, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

Jakobsen A

Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

References (29)

29 references, click to expand

The surgical management of stage I and stage II lung cancer.
Surg Oncol Clin N Am. 2011 Oct;20(4):701-20 PMID: 21986267
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
Int J Comput Assist Radiol Surg. 2013 Mar;8(2):181-91 PMID: 22644386
Free DNA in the serum of cancer patients and the effect of therapy.
Cancer Res. 1977 Mar;37(3):646-50 PMID: 837366
Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Nucl Med Commun. 2012 Jun;33(6):613-20 PMID: 22407127
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Clin Cancer Res. 2012 Feb 15;18(4):1177-85 PMID: 22228631
Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.
Int J Gynecol Cancer. 2011 Dec;21(9):1592-600 PMID: 21926912
Circulating cell free DNA: Preanalytical considerations.
Clin Chim Acta. 2013 Sep 23;424:222-30 PMID: 23727028
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 PMID: 10655437
Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Eur J Radiol. 2012 Dec;81(12):4179-84 PMID: 22884163
The origin and mechanism of circulating DNA.
Ann N Y Acad Sci. 2000 Apr;906:161-8 PMID: 10818614
Analysis of circulating tumor DNA to monitor metastatic breast cancer.
N Engl J Med. 2013 Mar 28;368(13):1199-209 PMID: 23484797
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Ann Surg. 2013 Feb;257(2):364-70 PMID: 22968069
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Acad Radiol. 2013 Jan;20(1):32-40 PMID: 22999369
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Clin Cancer Res. 2012 Apr 15;18(8):2391-401 PMID: 22492982
Cell-free nucleic acids as biomarkers in cancer patients.
Nat Rev Cancer. 2011 Jun;11(6):426-37 PMID: 21562580
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Drugs. 2012 Jun 19;72 Suppl 1:3-10 PMID: 22712792
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
JAMA. 2001 Feb 21;285(7):914-24 PMID: 11180735
Personalized medicine and treatment approaches in non-small-cell lung carcinoma.
Pharmgenomics Pers Med. 2012;5:113-23 PMID: 23226067
Metabolic tumor burden predicts for disease progression and death in lung cancer.
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):328-33 PMID: 17869659
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Radiology. 2012 Aug;264(2):559-66 PMID: 22692034
Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.
Future Oncol. 2011 Dec;7(12):1385-97 PMID: 22112315
REporting recommendations for tumour MARKer prognostic studies (REMARK).
Eur J Cancer. 2005 Aug;41(12):1690-6 PMID: 16043346
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38 PMID: 21946983
First line chemotherapy in advanced or metastatic NSCLC.
Ann Oncol. 2006 May;17 Suppl 5:v64-7 PMID: 16807466
Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET.
Cancer Invest. 2003;21(1):47-52 PMID: 12643009
Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.
Clin Transl Sci. 2012 Feb;5(1):65-70 PMID: 22376260
The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer.
Urol Oncol. 2011 Mar-Apr;29(2):124-9 PMID: 19762255
Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker.
Cancer. 2012 Jan 1;118(1):82-90 PMID: 21713763
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200 PMID: 19915839

Article Info

Journal

British journal of cancer

Abbr.

Br J Cancer

ISSN

1532-1827

DOI

10.1038/bjc.2013.705

Published

2014-01-21

Epub

2013-00-14

Pages

363-8

Language

English

Region

England

NLM ID

0370635

PMCID

PMC3899755

Subset

External Links

PubMed source DOI: 10.1038/bjc.2013.705 PMC Full Text View journal details

Analysis Services

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.

Contact

WeChat Official Account